PE Gasification Turbidity Adjustable For Treatment Of Chronic Kidney Disease Blood 3～4 Phase Of Clinical Research

Objective: through clinical research observation profit gasification turbidity adjustable for treatment of chronic kidney disease blood 3 ~ 4 period, qi deficiency and blood stasis syndrome of block turbid, efficacy, safety to delay the progress of chronic kidney disease and provide new ideas. Methods: a randomized, open and positive drug parallel controlled clinical research methods. Chronic kidney disease, early in treatment group and control group mid-term: each 25 cases, diet and symptomatic treatment in treatment group, on the basis of PE gasification turbidity adjustable blood square to add and subtract, water frying clothing, day one agent; The control group oral urine poisonous clear particles, early, middle and late daily of 5 grams (l bags), bedtime 10 grams (2 bags). Treatment 8 weeks. Results: (1) renal comparison: treatment after eight weeks, two groups of Scr are rising, Ccr all have declined, but the treatment groups before and after treatment, P no significant difference were greater than 0.05; Before and after the treatment control was significant difference (P < 0.05). Explain treatment group was better than control group in stable renal function. (2) hemoglobin comparison: treatment group therapy before treatment after a hemoglobin is increased, have significant difference (P﹤0.05); Before and after the treatment hemoglobin control compared the non-significance difference (P > 0.05). The treatment group compared with controls, the treatment group Hb rise compared with control more apparent, was significant difference (P﹤0.05). Explain the treatment group in improvements in renal anemia than control group. (3) syndromes curative effect comparison: after treatment, the two groups of eight weeks with total score syndromes before treatment are significant difference compared (P < 0.05), and the treatment group total score syndromes obviously lower than in control group (P < 0.05). (4) comprehensive effect comparison: in the treatment of 8 weeks, two groups of patients, the comprehensive effect quite was not statistically significant (P > 0.05).effect: after treatment, the two groups of eight weeks with total score syndromes before treatment are significant difference compared (P < 0.05), and the treatment group total score syndromes obviously lower than in control group (P < 0.05).